At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
00867 CMS
Closed 02-04 16:08:25
14.580
+0.100
+0.69%
High14.780Low14.280Vol3.06M
Open14.450D1 Closing14.480Amplitude3.45%
Mkt Cap35.58BTradable Cap35.57BTotal Shares2.44B
T/O44.49MT/O Rate0.13%Tradable Shares2.44B
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
China Medical System Receives Regulatory Nod to Begin Trials of CMS-D017
MT Newswires Live  ·  12:03
China Medical System Receives Regulatory Nod to Begin Trials of CMS-D017
CMS (00867) Self-Developed Innovative Drug CMS-D017 Capsule Receives Clinical Trial Approval Notice for Complement-Mediated Kidney Diseases
Stock News  ·  02-03 21:06
CMS (00867) Self-Developed Innovative Drug CMS-D017 Capsule Receives Clinical Trial Approval Notice for Complement-Mediated Kidney Diseases
China Medical System Holdings Limited Approval of Drug Clinical Trials for Cmkd Indication of Innovative Drug CMS-D017
THOMSON REUTERS  ·  02-03 21:00
China Medical System Holdings Limited Approval of Drug Clinical Trials for Cmkd Indication of Innovative Drug CMS-D017
China Medical System Holdings erhält Zulassung für klinische Studie mit CMS-D017 in China
Reuters  ·  02-03 20:56
China Medical System Holdings erhält Zulassung für klinische Studie mit CMS-D017 in China
China Medical System Holdings - CMS-D017 Capsules Receive Clinical Trial Approval From Nmpa
THOMSON REUTERS  ·  02-03 20:56
China Medical System Holdings - CMS-D017 Capsules Receive Clinical Trial Approval From Nmpa
CMS (00867) Announces January 2026 Monthly Return with No Share Capital Changes
Bulletin Express  ·  02-02 17:52
CMS (00867) Announces January 2026 Monthly Return with No Share Capital Changes
Hong Kong Stocks Movement | CMS (00867) Rises Over 3% as Institutions Note Ruxolitinib Cream's Domestic Approval Could Fill the Gap in Vitiligo Targeted Therapy
Stock News  ·  02-02 10:07
Hong Kong Stocks Movement | CMS (00867) Rises Over 3% as Institutions Note Ruxolitinib Cream's Domestic Approval Could Fill the Gap in Vitiligo Targeted Therapy
CICC Maintains "Outperform" Rating on CMS (00867), Raises Target Price to HK$16.5
Stock News  ·  02-02 09:28
CICC Maintains "Outperform" Rating on CMS (00867), Raises Target Price to HK$16.5
China Medical System Holdings Limited Approval of Clinical Trials for Pnh of Innovative Drug Complement Factor B Inhibitor CMS-D017
THOMSON REUTERS  ·  01-30
China Medical System Holdings Limited Approval of Clinical Trials for Pnh of Innovative Drug Complement Factor B Inhibitor CMS-D017
China Medical System - CMS-D017 Capsules Obtain Drug Clinical Trial Approval From Nmpa
THOMSON REUTERS  ·  01-30
China Medical System - CMS-D017 Capsules Obtain Drug Clinical Trial Approval From Nmpa
China Medical System Holdings Receives NMPA Approval to Begin Clinical Trials for CMS-D017
Reuters  ·  01-30
China Medical System Holdings Receives NMPA Approval to Begin Clinical Trials for CMS-D017
China Medical System Unit Secures New Drug Application Approval in China for Vitiligo Drug
MT Newswires Live  ·  01-30
China Medical System Unit Secures New Drug Application Approval in China for Vitiligo Drug
CMS (00867): Innovative Drug Ruxolitinib Phosphate Cream Approved in China, Marking First and Only Targeted Therapy for Vitiligo
Stock News  ·  01-30
CMS (00867): Innovative Drug Ruxolitinib Phosphate Cream Approved in China, Marking First and Only Targeted Therapy for Vitiligo
China Medical System Holdings - New Drug Application of Ruxolitinib Phosphate Cream Approved in China
THOMSON REUTERS  ·  01-30
China Medical System Holdings - New Drug Application of Ruxolitinib Phosphate Cream Approved in China
China Medical System Holdings Wins NMPA Approval for Ruxolitinib Cream for Vitiligo
Reuters  ·  01-30
China Medical System Holdings Wins NMPA Approval for Ruxolitinib Cream for Vitiligo
With 51% ownership, China Medical System Holdings Limited (HKG:867) insiders have a lot riding on the company's future
Simply Wall St.  ·  01-29
With 51% ownership, China Medical System Holdings Limited (HKG:867) insiders have a lot riding on the company's future
CMS Securities Initiates Coverage on CMS (00867) with "Strongly Recommend" Rating, Citing Innovation and Internationalization Driving Commercial Leader into New Phase
Stock News  ·  01-21
CMS Securities Initiates Coverage on CMS (00867) with "Strongly Recommend" Rating, Citing Innovation and Internationalization Driving Commercial Leader into New Phase
An Insider At China Medical System Holdings Lowered Their Holding Recently
Simply Wall St.  ·  01-08
An Insider At China Medical System Holdings Lowered Their Holding Recently
China Medical System Holdings (SEHK:867): Valuation Check After Y-3 Stroke Drug NDA Acceptance and Phase III Success
Simply Wall St.  ·  2025-12-17
China Medical System Holdings (SEHK:867): Valuation Check After Y-3 Stroke Drug NDA Acceptance and Phase III Success
Guoyuan International Initiates "Buy" Rating on CMS (00867) with Target Price of HK$17.68
Stock News  ·  2025-12-17
Guoyuan International Initiates "Buy" Rating on CMS (00867) with Target Price of HK$17.68

Introduction

Company Name.
CMS
Affiliated Markets:
SEHK
Listing Date:
--
Main Business:
China Medical System Holdings Ltd is an investment holding company principally engaged in the production of medicines, as well as marketing, promotion and sales of drugs. The Company's products include Plendil, Ursofalk, Augentropfen Stulln Mono Eye Drops, Hirudoid, Atopic Piel Series and Vmonalisa, among others. Its major marketed products cover the cardio-cerebrovascular, gastroenterology, ophthalmology, dermatology and medical aesthetic fields. The Company distributes its products within domestic market and to overseas markets.
Issue price:
--